Real World Trial Show Efficacy of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice Interview with:
Jørgen Vestbo DMSc FRCP FERS

Professor of  Respiratory Medicine
Division of Infection, Immunity and Respiratory Medicine
University of Manchester
Education and Research Centre
University Hospital of South Manchester
Manchester What is the background for this study? What are the main findings?

Response: Efficacy studies are limited in their usefulness to clinicians as there are often restricted inclusion criteria, with many exclusion criteria and patients are followed closely with high adherence to study treatment. They therefore show what the drugs can do but not necessarily what they do do in the real world.

Randomised studies in everyday practice, not limiting the entry (effectiveness trials) are therefore needed.

In our study we showed that it is feasible to do randomised studies in the “real world”.

Our study showed that a simple treatment with a once-daily combination of an inhaled corticosteroid and a long-acting beta-agonist (Breo/Relvar) was superior to the usual care chose by the patients’ general practitioners to manage their COPD. What should readers take away from your report?

Response: Simple treatments work in the real world and that the usual efficacy trials in tightly controlled trials need to be supplemented by randomised trials in everyday practice. What recommendations do you have for future research as a result of this study?

Response: Try to persuade other pharmaceutical companies to put their drugs to the test in the real world. If these studies are not requested, other companies may shy away from them! Thank you for your contribution to the community


Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice

Jørgen Vestbo, D.M.Sc., David Leather, M.B., Ch.B., Nawar Diar Bakerly, M.D., John New, M.B., B.S., J. Martin Gibson, Ph.D., Sheila McCorkindale, M.B., Ch.B., Susan Collier, M.B., Ch.B., Jodie Crawford, M.Sc., Lucy Frith, M.Sc., Catherine Harvey, D.Phil., Henrik Svedsater, Ph.D., and Ashley Woodcock, M.D., for the Salford Lung Study Investigators*

September 4, 2016DOI: 10.1056/NEJMoa1608033

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″]




Last Updated on September 7, 2016 by Marie Benz MD FAAD